United States: The Proposed Common Rule: The Tribe Has Spoken, And They Have Concerns

An overview of stakeholder comments on the redefinition of "biospecimen" as a "human subject" and the consent requirements for secondary use of these biospecimens.

On September 8, 2015, the U.S. Department of Health and Human Services (HHS) and 15 other federal agencies issued a notice of proposed rulemaking (NPRM) to update the federal policy for the Protection of Human Subjects, more commonly known as the Common Rule. More than 2,000 comments were submitted in response to the NPRM. This update focuses on the discussion surrounding the redefinition of "biospecimen" as a "human subject" and the consent requirements for secondary use of these biospecimens. In sum, stakeholders' general response to these proposed changes was unenthusiastic and evidenced a concern for the future of cost-efficient research. What the relevant agencies do with these comments is likely years away.

Redefining Biospecimen

The Common Rule defines "human subject" as (1) a living individual about whom an investigator conducting research obtains data through intervention or interaction with the individual or (2) individually identifiable private information that may readily lead to the ascertainment of the individual's identity. Currently, researchers may use biospecimens that have been stripped of all identifiers without obtaining the individual's consent because the data and specimens do not meet the definition of "human subject."

The NPRM expressed concern that technologic advances and whole-genome sequencing could result in the re-identification of biospecimens or data that have been stripped of identifiers. As a result, the NPRM proposed to change the definition of "human subject" to include all biospecimens, regardless of identifiability. Researchers would then be required to obtain consent from patients to use these biospecimens for unspecified secondary research purposes different from the original purpose for which they were collected. The NPRM proposed doing so by means of a broad consent.

Concerns and Criticisms

While stakeholders universally complimented the agencies' attempt to update and modernize the Common Rule, they nevertheless offered stark differences in their views of some of the major proposed changes. For example, the American Medical Association (AMA) stated that it "strongly support[s] the development of guidance specific to research involving biospecimens or identifiable private information, including the secondary use of specimens or information initially collected for non-research purposes." Others were less complimentary. Representing five independent institutional review boards, the WIRB-Copernicus Group commented that the distinctions between biospecimens and other types of data were "confusing and not warranted," and it encouraged HHS to treat biospecimens and data the same under the regulations, even if biospecimens are theoretically identifiable.

Acknowledging that informed consent to use identifiable biospecimens remained crucial for patient autonomy, stakeholders representing the medical device, pharmaceutical and biotechnology manufacturing industries expressed concerns over the future of research if surplus biospecimens lacking individual identifiers also required consent before use. Because each biospecimen's owner would need to be contacted and consented, the Advanced Medical Technology Association (AdvaMed) estimated that costs to conduct research would raise 10- to 50-fold and studies that normally take days or weeks would require months and years. This, AdvaMed stated, "would be starkly inconsistent with FDA's statutory and regulatory mission of promoting public health and ensuring that medical devices provide a reasonable assurance of safety and effectiveness."

Pharmaceutical Research and Manufacturers of America (PhRMA) similarly observed that researchers and hospital administrators overseeing biorepositories would need to develop tracking systems to match biospecimens in storage with the consent status of the person who provided the specimen. The AMA questioned whether the biorepository or the requesting researcher would be responsible for contacting and consenting patients whose specimens were not originally donated for research. This administrative burden and consideration of non-research patients' privacy may lead hospitals to forgo making samples available to researchers.

AdvaMed, PhRMA and St. Jude Children's Research Hospital all noted the push toward precision medicine and translational research. These cutting-edge studies require convenient access to vast stores of samples with multiple biomarkers for cancer and other diseases. Identifying and contacting thousands of patients certainly is not practicable, and may be unethical, according to AdvaMed, as it would require researchers to contact terminally ill patients possessing unique biomarkers to request the use of their already available biospecimens. Combined, the stakeholders expressed misgivings that this could undermine the intent of the Common Rule, delay important breakthroughs in drug and device development, and compromise the principles of respect, beneficence and justice described in the Belmont Report.

Stakeholder comments revealed similar concerns about patient privacy. For example, both AdvaMed and the Association of Clinical Research Organizations (ACRO) cautioned that researchers would need to track previously unidentifiable biospecimens with a unique patient identifier to determine whether the patient granted consent for unspecified future use. Additionally, researchers would need to monitor whether the patient withdrew consent or whether such consent expired, given the NPRM's proposed 10-year duration for broad consent – an "arbitrary" and "difficult to track and enforce" period, according to St. Jude Children's Research Hospital.

Interestingly, ACRO hypothesized that redefining "biospecimen" as "human subject" may have unintended political and ethical consequences, co-opted by groups citing a federal definition of "personhood" as precedence for what "human life" means. Such a consequence would be entirely unrelated to the Common Rule's intent.

Suggestions

Along with criticisms, stakeholders had a number of thoughtful suggestions. Many advocated for an "opt-out" broad consent option rather than an "opt-in" option. In an opt-out option, patients would assent to the use of non-identifiable biospecimens for unspecified future research unless they affirmatively said no. As ACRO advocated, patient education at the point of specimen collection regarding de-identification of biospecimens and the risk of re-identification would increase patient autonomy by giving patients the opportunity to discuss privacy risks rather than distracting them with a misleading consent alluding to unspecified future research. AdvaMed further argued that an opt-in approach would likely become routine rather than being a meaningful discussion about the likelihood of risk, thereby undermining patient autonomy. PhRMA agreed, stating that an opt-out approach would maximize the opportunities for sample donations and enhance scientific research without increasing risks to subjects.

Regarding the potential future risk of re-identification through technologic advances, AdvaMed reminded the agencies of their regulatory authority to "encourag[e] HHS under its existing statutory authorities ... to impose administrative, regulatory, civil, and even criminal penalties on ... the unauthorized re-identification of biospecimens that are not individually identifiable." ACRO also cited the success of data use agreements under HIPAA with regard to a limited data set. These data use agreements allow for sharing of data while specifically prohibiting re-identification of de-identified data through penalties and other restrictions. A similar application could be used for shared, unidentifiable biospecimens. These regulatory and contractual considerations would protect patient privacy without compromising scientific research.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.